Wiskott-Aldrich syndrome complicated with IgG4-related Sclerosing disease: A case report and literature review
Main Article Content
Keywords
IgG4-related disease, lymphadenomegaly, rare disease, Wiskott-Aldrich Syndrome
Abstract
Wiskott-Aldrich Syndrome (WAS) is an X-linked immunodeficiency characterized by eczema, microthrombocytopenia, and recurrent infections. Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory disorder involving various organs. We present a 34-year-old male with WAS who developed cervical lymphadenopathy and parotid gland swelling. Initial biopsies were inconclusive and imaging suggested pleomorphic adenoma. Given the persistent cervical lymphadenopathy and the underlying immunodeficiency, lymphoma was also considered in the differential diagnosis. However, histopathological examination of excised salivary gland and lymph nodes revealed lymphoplasmacytic and eosinophilic infiltrates, numerous IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis, consistent with IgG4-RD. The patient responded well to prednisone therapy. This case emphasizes the importance of considering IgG4-RD in the differential diagnosis of lymphoproliferative lesions in immunodeficient individuals and highlights the diagnostic value of histopathological evaluation in excisional tissue specimens. To our knowledge, this represents a rare coexistence of WAS and IgG4-RD not previously reported in the literature.
References
2 Aldrich RA, Steinberg AG, Campbell DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954;13:133–9.
3 Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
4 Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78(4):635–44. 10.1016/0092-8674(94)90528-2
5 Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: A comprehensive review. Ann N Y Acad Sci. 2013;1285:26–43. 10.1111/nyas.12049
6 Cleland SY, Siegel RM. Wiskott-Aldrich syndrome at the nexus of autoimmune and primary immunodeficiency diseases. FEBS Lett. 20111;585(23):3710–4. 10.1016/j.febslet.2011.10.031
7 Puck JM, Candotti F. Lessons from the Wiskott-Aldrich syndrome. N Engl J Med. 2006;355(17):1759–61. 10.1056/NEJMp068209
8 Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90(7):2680–9
9 Imai K, Nonoyama S, Ochs HD. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. Curr Opin Allergy Clin Immunol. 2003;3(6):427–36. 10.1097/00130832-200312000-00003
10 Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876–85.
11 Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–71. 10.1016/S0140-6736(14)60720-0.
12 Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51. 10.1056/NEJMra1104650
13 Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702–14. 10.1038/s41584-020-0500-7
14 Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92. 10.1038/modpathol.2012.72
15 Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72(1): 7–19. 10.1002/art.41120
16 Perugino CA, AlSalem SB, Mattoo H, Della-Torre E, Mahajan V, Ganesh G, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol. 2019;143(2):736–45.e6. 10.1016/j.jaci.2018.05.011.
17 Du H, Shi L, Chen P, Yang W, Xun Y, Yang C, et al. Prohibitin is involved in patients with IgG4-related disease. PLoS One. 2015;10(5):e0125331. 10.1371/journal.pone.0125331.
18 Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International Consensus Guidance Statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.
19 Smit W, Barnes E. The emerging mysteries of IgG4-related disease. Clin Med. 2014;14(Suppl 6):s56–60. 10.7861/clinmedicine.14-6-s56. PMid: 25468921.
20 Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5. 10.1136/annrheumdis-2014-205233. Epub 2014 May 9. PMid: 24817416; PMCID: PMC4656194.
21 Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4-related disease. BMJ. 2020;369:m1067.
22 Tang J, Cai S, Ye C, Dong L. Biomarkers in IgG4-related disease: A systematic review. Semin Arthritis Rheum. 2020;50(2): 354–9. 10.1016/j.semarthrit.2019.06.018
23 Chan ASY, Mudhar H, Shen SY, Lang SS, Fernando M, Hilmy MH, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): Potential use in IgG4-RD assessment. Br J Ophthalmol. 2017;101(11):1576–82. 10.1136/bjophthalmol-2017-310148. Epub 2017 Mar 28. PMid: 28351925.